A 68-year-old man from Delhi presents with progressive lower urinary tract symptoms for 8 months. He complains of nocturia (4–5 times per night), weak urinary stream, hesitancy, and incomplete emptying. He denies hematuria, fever, or weight loss. Digital rectal examination reveals a smooth, firm, symmetrically enlarged prostate without nodules. Post-void residual urine is 120 mL. Serum PSA is 2.8 ng/mL. Uroflowmetry shows peak flow of 8 mL/s (normal >15 mL/s). Which of the following is the most appropriate next step in management?

Explanation

## Clinical Assessment of BPH This patient presents with classic lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) with objective evidence of obstruction (reduced peak flow, elevated post-void residual, smooth symmetric prostate enlargement). ### Diagnostic Confirmation **Key Point:** The combination of clinical symptoms, digital rectal examination findings (smooth, symmetric enlargement), reduced peak flow on uroflowmetry (8 mL/s), and elevated post-void residual (120 mL) confirms BPH-related lower urinary tract obstruction. **High-Yield:** International Prostate Symptom Score (IPSS) and uroflowmetry are the gold standard non-invasive tools for diagnosing and grading BPH severity. PSA is normal, ruling out malignancy. ### Management Algorithm for BPH ```mermaid flowchart TD A[BPH diagnosed: LUTS + obstruction]:::outcome --> B{Symptoms severity?}:::decision B -->|Mild-Moderate| C[Lifestyle modifications + watchful waiting]:::action B -->|Moderate-Severe| D[Pharmacotherapy trial]:::action D --> E[Alpha-1 antagonist ± 5-alpha reductase inhibitor]:::action E --> F{Response after 4-6 weeks?}:::decision F -->|Good| G[Continue medical management]:::action F -->|Poor/Intolerable AE| H[Consider invasive options]:::action H --> I[TURP, laser, or other procedures]:::action A --> J{Acute retention or complications?}:::decision J -->|Yes| K[Catheterization + urgent intervention]:::urgent ``` ### Why Alpha-1 Antagonist Is First-Line | Feature | Alpha-1 Antagonist | 5-Alpha Reductase Inhibitor | |---------|-------------------|---------------------------| | Onset | 1–2 weeks | 3–6 months | | Mechanism | Relaxes smooth muscle in prostate & bladder neck | Reduces prostate volume | | Best for | Moderate LUTS, rapid symptom relief | Large prostate (>40 g), PSA >1.5 | | Side effects | Dizziness, retrograde ejaculation | Sexual dysfunction, gynecomastia | **Clinical Pearl:** Tamsulosin (0.4 mg once daily) is preferred over doxazosin or terazosin because it has uroselective alpha-1A antagonism with fewer cardiovascular side effects and less orthostatic hypotension. **Key Point:** Lifestyle modifications (fluid restriction, caffeine/alcohol avoidance, timed voiding, pelvic floor exercises) should accompany pharmacotherapy in all cases. ### Why TURP Is Not First-Line Here TURP is reserved for: - Failure of medical therapy after 4–6 weeks of adequate trial - Recurrent UTIs due to high post-void residual - Recurrent hematuria from BPH - Acute retention refractory to catheter trial - Patient preference after counseling This patient has not yet received a trial of medical therapy, so TURP is premature.